Latest Conference Articles

October 7th 2015, 12:02pm

European Cancer Congress

Philip Poortmans, MD, PhD, head of Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands, and president of European Society for Therapeutic Radiology and Oncology, discusses the impact of a multidisciplinary approach on survivorship and side effect management for patients with prostate cancer.

October 6th 2015, 1:05pm

European Cancer Congress

Matteo Lambertini, MD, Department of Medical Oncology, U.O. Oncologia Medica A, Hospital San Martino, Genova, Italy, discusses the use of luteinizing hormone-releasing hormone agonists (LHRHa) during chemotherapy to preserve ovarian function and fertility in patients with breast cancer.

October 2nd 2015, 2:21pm

European Cancer Congress

Andrea Apolo, MD, medical oncologist at the National Cancer Institute and chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses treatment challenges for patients with refractory, metastatic urothelial carcinoma.

October 1st 2015, 8:52am

European Cancer Congress

Johan F. Vansteenkiste, MD, PhD, professor of Internal Medicine at Katholieke Universiteit Leuven, Belgium, discusses the primary analysis of the phase II POPLAR study, which looked at atezolizumab versus docetaxel in patients with non–small cell lung cancer (NSCLC).

September 30th 2015, 2:47pm

European Cancer Congress

Catherine Pietanza, MD, assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses novel targeted therapy rovalpituzumab tesirine (Rova-T), which showed activity in relapsed and refractory small cell lung cancer (SCLC) in a recent phase I study.

September 30th 2015, 7:04am

European Cancer Congress

Treatment with telotristat etiprate reduced the average number of daily bowel movements by up to 35% for patients with carcinoid syndrome that was not adequately controlled by a somatostatin analog.

September 29th 2015, 8:39am

European Cancer Congress

Treatment with the frontline combination of erlotinib and bevacizumab was highly effective in patients with advanced non–small cell lung cancer who harbored an EGFR T790M mutation.

September 28th 2015, 4:15pm

European Cancer Congress

Treatment with nivolumab reduced the risk of death by 28% compared with docetaxel for patients with previously treated nonsquamous non–small cell lung cancer.

September 28th 2015, 3:13pm

European Cancer Congress

The antibody-drug conjugate rovalpituzumab tesirine demonstrated activity across a range of patients with relapsed and refractory small-cell lung cancer.

September 28th 2015, 11:38am

European Cancer Congress

Data from the pivotal KEYNOTE-001 trial showing pembrolizumab's efficacy in pretreated non–small cell lung cancer (NSCLC) were presented at the 2015 European Cancer Congress, just days before the FDA is scheduled to make its approval decision on the PD-1 inhibitor in this setting.

September 28th 2015, 9:23am

European Cancer Congress

Adding fosaprepitant (Emend) to an antiemetic regimen significantly improved emesis control versus standard care in women receiving radiotherapy and cisplatin for cervical cancer.

September 28th 2015, 7:14am

European Cancer Congress

Andrea B. Apolo, MD, medical oncologist at the National Cancer Institute, chief of the bladder cancer section of the Genitourinary Malignancies Branch, discusses a phase 1b trial investigating avelumab, an anti-PD-L1 antibody, in patients with refractory, metastatic urothelial carcinomas.

September 28th 2015, 5:44am

European Cancer Congress

Dirk Arnold, MD, Director Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, Arnold Discusses the CONSIGN Study.

September 27th 2015, 2:01pm

European Cancer Congress

The combination of dabrafenib plus trametinib improved overall survival by 7.6 months compared with single-agent vemurafenib in patients with unresectable or metastatic BRAFV600E/K-mutant melanoma.

September 27th 2015, 11:57am

European Cancer Congress

The combination of the attenuated oncolytic virus talimogene laherparepvec and the immune checkpoint inhibitor pembrolizumab for unresectable melanoma has passed an early safety evaluation.

September 27th 2015, 10:49am

European Cancer Congress

Second-line atezolizumab demonstrated significant clinical benefit in patients with metastatic urothelial carcinoma who had a poor prognosis after progressing following platinum-based chemotherapy.

September 27th 2015, 10:20am

European Cancer Congress

Inhibition of PD-L1 with atezolizumab demonstrated significant clinical efficacy as monotherapy in patients with advanced non-small cell lung cancer.

September 27th 2015, 9:07am

European Cancer Congress

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine discusses a phase II trial investigating the PD-1 blockade pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).

September 27th 2015, 9:04am

European Cancer Congress

Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.

September 27th 2015, 8:48am

European Cancer Congress

Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).